Efflux pumps in Mycobacterium tuberculosis and their inhibition to tackle antimicrobial resistance.
Mycobacterium tuberculosis
antimicrobial resistance
efflux pump inhibitor
efflux pumps
Journal
Trends in microbiology
ISSN: 1878-4380
Titre abrégé: Trends Microbiol
Pays: England
ID NLM: 9310916
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
06
01
2021
revised:
04
05
2021
accepted:
05
05
2021
pubmed:
31
5
2021
medline:
8
4
2022
entrez:
30
5
2021
Statut:
ppublish
Résumé
Tuberculosis (TB), an infectious disease caused by the bacterium Mycobacterium tuberculosis, was the leading cause of mortality worldwide in 2019 due to a single infectious agent. The growing threat of strains of M. tuberculosis untreatable by modern antibiotic regimens only exacerbates this problem. In response to this continued public health emergency, research into methods of potentiating currently approved antimicrobial agents against resistant strains of M. tuberculosis is an urgent priority, and a key strategy in this regard is the design of mycobacterial efflux pump inhibitors (EPIs). This review summarises the current state of knowledge surrounding drug-related efflux pumps in M. tuberculosis and presents recent updates within the field of mycobacterial EPIs with a view to aiding the design of an effective adjunct therapy to overcome efflux-mediated resistance in TB.
Identifiants
pubmed: 34052094
pii: S0966-842X(21)00123-2
doi: 10.1016/j.tim.2021.05.001
pii:
doi:
Substances chimiques
Anti-Infective Agents
0
Antitubercular Agents
0
Bacterial Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
57-68Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/T007648/1
Pays : United Kingdom
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.